Literature DB >> 17958541

An extensive polymerase chain reaction-allele-specific polymorphism strategy for clinical ABO blood group genotyping that avoids potential errors caused by null, subgroup, and hybrid alleles.

Bahram Hosseini-Maaf1, Asa Hellberg, M Alan Chester, Martin L Olsson.   

Abstract

BACKGROUND: ABO genotyping is complicated by the remarkable diversity at the ABO locus. Recombination or gene conversion between common alleles may lead to hybrids resulting in unexpected ABO phenotypes. Furthermore, numerous mutations associated with weak subgroups and nondeletional null alleles should be considered. All known ABO genotyping methods, however, risk incorrect phenotype predictions if any such alleles are present. STUDY DESIGN AND METHODS: An extensive set of allele-specific primers was designed to accomplish hybrid-proof multiplex polymerase chain reaction (PCR) amplification of DNA fragments for detection of ABO alleles. Results were compared with serologic findings and ABO genotypes defined by previously published PCR-restriction fragment length polymorphism/PCR-allele-specific polymorphism (ASP) methods or DNA sequencing.
RESULTS: Phenotypically well-characterized samples from blood donors with common blood groups and rare-subgroup families were analyzed. In addition to the commonly encountered alleles (A1, A1(467C>T), A2, B, O1, O1v, and O2), the new method can detect hybrid alleles thanks to long-range amplification across intron 6. Four of 12 PCR-ASP procedures are used to screen for multiple infrequent subgroup and null alleles. This concept allows for a low-resolution typing format in which the presence of, for example, a weak subgroup or cis-AB/B(A) is indicated but not further defined. In an optional high-resolution step, more detailed genotype information is obtained.
CONCLUSION: A new genotyping approach has been developed and evaluated that can correctly identify ABO alleles including nondeletional null alleles, subgroups, and hybrids resulting from recombinational crossing-over events between exons 6 and 7. This approach is clinically applicable and decreases the risk for erroneous ABO phenotype prediction compared to previously published methods.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958541     DOI: 10.1111/j.1537-2995.2007.01436.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  FUT1 mutations responsible for the H-deficient phenotype in the Polish population, including the first example of an abolished start codon.

Authors:  Bogumila Michalewska; Martin L Olsson; Grazyna Naremska; Jolanta Walenciak; Annika K Hult; Agnieszka Ozog; Katarzyna Guz; Ewa Brojer; Jill R Storry
Journal:  Blood Transfus       Date:  2016-11-21       Impact factor: 3.443

2.  Mixed field reactions in ABO and Rh typing chimerism likely resulting from twin haematopoiesis.

Authors:  Christopher Sharpe; Debra Lane; Jacqueline Cote; Bahram Hosseini-Maaf; Mindy Goldman; Martin L Olsson; Annika K Hult
Journal:  Blood Transfus       Date:  2014-03-19       Impact factor: 3.443

3.  Evidence of Endothelial Activation in Asymptomatic Plasmodium falciparum Parasitemia and Effect of Blood Group on Levels of von Willebrand Factor in Malaria.

Authors:  Gregory S Park; Kathleen F Ireland; Robert O Opoka; Chandy C John
Journal:  J Pediatric Infect Dis Soc       Date:  2012-03-01       Impact factor: 3.164

4.  Establishing Blood Group Genotyping to Resolve ABO Discrepancies in Iran.

Authors:  M Khorshidfar; A Chegini; A A Pourfathollah; A Oodi; N Amirizadeh
Journal:  Indian J Hematol Blood Transfus       Date:  2018-11-16       Impact factor: 0.900

5.  ABO chimerism determined by real-time polymerase chain reaction analysis after ABO-incompatible haematopoietic stem cell transplantation.

Authors:  Feng Liu; Guining Li; Xiaolu Mao; Lihua Hu
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

6.  The development of severe neonatal alloimmune thrombocytopenia due to anti-HPA-1a antibodies is correlated to maternal ABO genotypes.

Authors:  Maria Therese Ahlen; Anne Husebekk; Mette Kjær Killie; Jens Kjeldsen-Kragh; Martin L Olsson; Bjørn Skogen
Journal:  Clin Dev Immunol       Date:  2011-11-02

7.  Highly parallel and short-acting amplification with locus-specific primers to detect single nucleotide polymorphisms by the DigiTag2 assay.

Authors:  Nao Nishida; Yoriko Mawatari; Megumi Sageshima; Katsushi Tokunaga
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

8.  Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells?

Authors:  Guido Moll; Annika Hult; Lena von Bahr; Jessica J Alm; Nina Heldring; Osama A Hamad; Lillemor Stenbeck-Funke; Stella Larsson; Yuji Teramura; Helene Roelofs; Bo Nilsson; Willem E Fibbe; Martin L Olsson; Katarina Le Blanc
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

Review 9.  Blood Group Testing.

Authors:  Hong-Yang Li; Kai Guo
Journal:  Front Med (Lausanne)       Date:  2022-02-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.